文献速递肿瘤 PET/CT神经核医学

人工智能在肿瘤分子PET显像中的应用:超越[18F]F-FDG示踪剂的叙述性综述第二部分——[18F]F-FLT、[18F]F-FET、[11C]C-MET及其他不常用示踪剂

Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and Other Less-Commonly Used Radiotracers.
PubMed 文献 · Semin Nucl Med · 2024-02-07

本叙述性综述总结了人工智能(AI)与PET影像组学在非[18F]F-FDG示踪剂中的应用,重点涵盖[18F]F-FET、[18F]F-FLT和[11C]C-MET,并提及[18F]F-DOPA、[18F]F-FACBC、[18F]F-NaF、[68Ga]Ga-CXCR-4和[18F]F-FMISO等示踪剂。基于这些示踪剂的PET影像组学模型在肿瘤分级、鉴别假性进展与真性进展、预测生存及指导靶区勾画等方面显示出潜力。结论认为AI可提升特定适应证下PET显像的诊断性能。

要点

  • [18F]F-FET PET影像组学特征可能有助于胶质瘤精确勾画、分级及鉴别假性进展与真性进展。
  • [18F]F-FLT PET特征与Ki-67及患者预后相关,AI PET容积分析在骨髓保护适应性放疗靶区引导中显示初步前景。
  • [11C]C-MET PET影像组学模型在预测肿瘤分级、鉴别复发与放射性坏死及治疗监测中表现可接受。

核心结论

  • 使用超越[18F]F-FDG的示踪剂时,AI可改善PET显像在特定适应证中的诊断性能,并通过提供肉眼常无法检测的特征帮助临床医生日常实践。

研究设计与样本

  • 叙述性综述,总结AI与PET影像组学在非[18F]F-FDG示踪剂中的应用,重点为[18F]F-FLT、[18F]F-FET和[11C]C-MET,并涉及其他不常用示踪剂。

主要发现

  • [18F]F-FET-PET使用的非天然氨基酸可被肿瘤细胞摄取,在病灶检测和肿瘤表征方面显示潜力,尤其能反映胶质瘤异质性。
  • [18F]F-FET-PET纹理特征可能为精确勾画(指导活检和治疗)提供大量信息,鉴别低级别与高级别胶质瘤及相关野生型基因型,并区分假性进展与真性进展。
  • 使用临床参数和[18F]F-FET-PET影像组学特征构建的模型在胶质母细胞瘤患者生存分层中显示可接受的结果。
  • [18F]F-FLT-PET特征与Ki-67及患者预后相关,基于该增殖标志物的AI PET容积分析在引导靶向骨髓保护适应性放疗方面显示有前景的初步结果。
  • [11C]C-MET在预测肿瘤分级、区分脑肿瘤复发与放射性坏死及治疗监测方面显示可接受的性能;[18F]F-DOPA、[18F]F-FACBC、[18F]F-NaF、[68Ga]Ga-CXCR-4和[18F]F-FMISO的影像组学特征也可能为肿瘤表征和疾病结局预测提供有用信息。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Following the previous part of the narrative review on artificial intelligence (AI) applications in positron emission tomography (PET) using tracers rather than 18F-fluorodeoxyglucose ([18F]F-FDG), in this part we review the impact of PET-derived radiomics data on the diagnostic performance of other PET radiotracers, 18F-O-(2-fluoroethyl)-L-tyrosine ([18F]F-FET), 18F-Fluorothymidine ([18F]F-FLT) and 11C-Methionine ([11C]C-MET). [18F]F-FET-PET, using an artificial amino acid taken up into upregulated tumoral cells, showed potential in lesion detection and tumor characterization, especially with its ability to reflect glioma heterogeneity. [18F]F-FET-PET-derived textural features appeared to have the potential to reveal considerable information for accurate delineation for guiding biopsy and treatment, differentiate between low-grade and high-grade glioma and related wild-type genotypes, and distinguish pseudoprogression from true progression. In addition, models built using clinical parameters and [18F]F-FET-PET-derived radiomics features showed acceptable results for survival stratification of glioblastoma patients. [18F]F-FLT-PET-based characteristics also showed potential in evaluating glioma patients, correlating with Ki-67 and patient prognosis. AI-based PET-volumetry using this radiotracer as a proliferation marker also revealed promising preliminary results in terms of guide-targeting bone marrow-preserving adaptive radiation therapy. Similar to [18F]F-FET, the other amino acid tracer which reflects cellular proliferation, [11C]C-MET, has also shown acceptable performance in predicting tumor grade, distinguishing brain tumor recurrence from radiation necrosis, and treatment monitoring by PET-derived radiomics models. In addition, PET-derived radiomics features of various radiotracers such as [18F]F-DOPA, [18F]F-FACBC, [18F]F-NaF, [68Ga]Ga-CXCR-4 and [18F]F-FMISO may also provide useful information for tumor characterization and predict of disease outcome. In conclusion, AI using tracers beyond [18F]F-FDG could improve the diagnostic performance of PET-imaging for specific indications and help clinicians in their daily routine by providing features that are often not detectable by the naked eye.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Eisazadeh R, Shahbazi-Akbari M, Mirshahvalad SA, et al. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and Other Less-Commonly Used Radiotracers. Semin Nucl Med. 2024. PMID: 38331629. doi:10.1053/j.semnuclmed.2024.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。